ESC/EAS 2025 focused update: dyslipidaemias
International ESC/EAS Current
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach F, et al. Eur Heart J. 2025;46:4359–4378
DOI 10.1093/eurheartj/ehaf190 · Summary checked against the source: 2026-11
Adds to (doesn't replace) ESC/EAS 2019. Pages are from Eur Heart J 2025;46:4359–4378.
What's new
| Topic | Recommendation | Class, level |
|---|---|---|
| Risk estimation | SCORE2 (age <70) and SCORE2-OP (≥70) for 10-year fatal and non-fatal CVD risk in apparently healthy people | I, B |
| CAC or subclinical plaque as a risk modifier at moderate risk or near decision thresholds | IIa, B | |
| Primary prevention | Drug treatment for very high risk with LDL ≥1.8 mmol/L (70 mg/dL), or high risk with LDL ≥2.6 mmol/L (100 mg/dL) despite lifestyle | I, A |
| Statin intolerance | Non-statin therapies with proven CV benefit (ezetimibe, PCSK9 mAb, bempedoic acid), alone or combined | I, A |
| Bempedoic acid when statins can't be taken | I, B | |
| Add bempedoic acid to maximal statin ± ezetimibe in high or very-high-risk patients not at goal | IIa, C | |
| Homozygous FH | Evinacumab (anti-ANGPTL3) from age 5 if not at goal | IIa, B |
| Acute coronary syndrome | Intensify lipid-lowering during the index admission if already on treatment | I, C |
| Treatment-naive and unlikely to reach goal on a statin alone: start high-intensity statin + ezetimibe in hospital | IIa, B | |
| Lp(a) | >50 mg/dL (105 nmol/L) = a CV risk-enhancing factor in all adults, risk rising with the level | IIa, B |
| Hypertriglyceridaemia | Icosapent ethyl 2 g twice daily with a statin in high or very-high-risk patients with TG 135–499 mg/dL | IIa, B |
| Volanesorsen 300 mg weekly for familial chylomicronaemia with TG >750 mg/dL | IIa, B | |
| HIV | Statin for everyone ≥40 with HIV in primary prevention, whatever their risk or LDL-C (watch interactions) | I, B |
| Cancer | Statins in adults at high or very high risk of chemotherapy cardiotoxicity, to reduce anthracycline cardiac dysfunction | IIa, B |
| Supplements | Supplements or vitamins without proven safety and LDL-lowering efficacy: not recommended | III, B |
Adapted from ESC/EAS 2025 Recommendation Tables 1–8 [p. 4367–4374]
Expected LDL-C reduction ranges from about 20% with ezetimibe alone to about 85% with a high-intensity statin, ezetimibe and a PCSK9 mAb combined; response varies between people, so check LDL-C 4–6 weeks after any change. [Figure 2 · p. 4368]
Clinical pearls
- SCORE2 / SCORE2-OP replace SCORE.
- After ACS: "the sooner, the lower, the better": statin + ezetimibe can start in hospital.
- Lp(a) >50 mg/dL is a risk enhancer.
- All adults ≥40 with HIV get a statin.
Classes and levels of evidence
How ESC/EAS 2025 focused update grades its recommendations. Adapted from ESC/EAS 2025 focused update Tables 1 and 2 [p. 4362]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| Class I | Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective | is recommended or is indicated |
| Class IIa | Weight of evidence or opinion is in favour of usefulness or efficacy | should be considered |
| Class IIb | Usefulness or efficacy is less well established by evidence or opinion | may be considered |
| Class III | Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful | is not recommended |
| Level | Meaning |
|---|---|
| Level A | Data from multiple randomised clinical trials or meta-analyses |
| Level B | Data from a single randomised clinical trial or large non-randomised studies |
| Level C | Consensus of expert opinion and/or small studies, retrospective studies, registries |
Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.